JP2002503459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002503459A5 JP2002503459A5 JP2000531540A JP2000531540A JP2002503459A5 JP 2002503459 A5 JP2002503459 A5 JP 2002503459A5 JP 2000531540 A JP2000531540 A JP 2000531540A JP 2000531540 A JP2000531540 A JP 2000531540A JP 2002503459 A5 JP2002503459 A5 JP 2002503459A5
- Authority
- JP
- Japan
- Prior art keywords
- fiber
- protein
- adenovirus
- gene
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 description 104
- 239000000835 fiber Substances 0.000 description 97
- 102000004169 proteins and genes Human genes 0.000 description 69
- 241000701161 unidentified adenovirus Species 0.000 description 67
- 210000004027 cell Anatomy 0.000 description 42
- 239000013598 vector Substances 0.000 description 37
- 238000000034 method Methods 0.000 description 36
- 239000003446 ligand Substances 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 28
- 108010073385 Fibrin Proteins 0.000 description 25
- 102000009123 Fibrin Human genes 0.000 description 20
- 229950003499 fibrin Drugs 0.000 description 19
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 18
- 108091026890 Coding region Proteins 0.000 description 16
- 239000013615 primer Substances 0.000 description 16
- 230000008685 targeting Effects 0.000 description 15
- 239000013638 trimer Substances 0.000 description 13
- 101710189104 Fibritin Proteins 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 238000005829 trimerization reaction Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000002845 virion Anatomy 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
- 229960002963 ganciclovir Drugs 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- -1 Amino Chemical group 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000701533 Escherichia virus T4 Species 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003580 lung surfactant Substances 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710198223 Capsid fiber protein Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000701796 Fowl aviadenovirus 1 Species 0.000 description 1
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 1
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- JPIYZTWMUGTEHX-UHFFFAOYSA-N auramine O free base Chemical compound C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 JPIYZTWMUGTEHX-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 108010046301 glucose peroxidase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7484498P | 1998-02-17 | 1998-02-17 | |
| US60/074,844 | 1998-02-17 | ||
| PCT/US1999/003233 WO1999041359A1 (en) | 1998-02-17 | 1999-02-16 | Modified adenovirus containing a fiber replacement protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002503459A JP2002503459A (ja) | 2002-02-05 |
| JP2002503459A5 true JP2002503459A5 (https=) | 2006-04-06 |
Family
ID=22122019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000531540A Pending JP2002503459A (ja) | 1998-02-17 | 1999-02-16 | 繊維置換タンパク質を含有する修飾されたアデノウィルス |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6210946B1 (https=) |
| EP (1) | EP1070118B1 (https=) |
| JP (1) | JP2002503459A (https=) |
| KR (1) | KR20010074429A (https=) |
| CN (1) | CN1297479A (https=) |
| AT (1) | ATE342350T1 (https=) |
| AU (1) | AU751542B2 (https=) |
| BR (1) | BR9908018A (https=) |
| CA (1) | CA2321135A1 (https=) |
| DE (1) | DE69933550T2 (https=) |
| IL (1) | IL137730A0 (https=) |
| NO (1) | NO20004563L (https=) |
| NZ (1) | NZ506451A (https=) |
| WO (1) | WO1999041359A1 (https=) |
| ZA (1) | ZA200004208B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050095231A1 (en) * | 1998-02-17 | 2005-05-05 | Curiel David T. | Modified adenovirus containing a fiber replacement protein |
| US6815200B1 (en) * | 1998-02-17 | 2004-11-09 | The Uab Research Foundation | Modified adenovirus containing a fiber replacement protein |
| AU4070499A (en) | 1998-04-30 | 1999-11-16 | Cornell Research Foundation Inc. | Adenoviral vectors with tandem fiber proteins |
| US6455314B1 (en) | 1998-09-11 | 2002-09-24 | Genvec, Inc. | Alternatively targeted adenovirus |
| US6649396B1 (en) * | 1999-02-05 | 2003-11-18 | Uab Research Foundation | Fiber receptor-independent system for the propagation of adenoviral vectors |
| WO2001002431A1 (en) * | 1999-07-06 | 2001-01-11 | Got-A-Gene Ab | Recombinant adenovirus |
| CA2407518A1 (en) * | 2000-04-26 | 2001-11-01 | Crucell Holland B.V. | Adenovirus vectors with knobless fibers, and their uses |
| US7332337B2 (en) * | 2000-05-16 | 2008-02-19 | Galapagos Nv | Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells |
| AU6368901A (en) | 2000-05-31 | 2001-12-11 | Univ Saskatchewan | Modified bovine adenovirus having altered tropism |
| JP3635462B2 (ja) * | 2000-05-31 | 2005-04-06 | 国立医薬品食品衛生研究所長 | アデノウイルスベクター |
| GB0017720D0 (en) * | 2000-07-19 | 2000-09-06 | Got A Gene Ab | Modified virus |
| EP1409748B1 (en) * | 2001-06-22 | 2011-10-26 | The Trustees of The University of Pennsylvania | Recombinant Adenoviruses comprising simian adenovirus proteins and uses thereof. |
| US6905678B2 (en) * | 2001-07-07 | 2005-06-14 | Crucell Holland B.V. | Gene delivery vectors with cell type specificity for mesenchymal stem cells |
| EP1516055A4 (en) * | 2002-01-24 | 2007-08-08 | Scripps Research Inst | FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS |
| US20050003548A1 (en) * | 2002-07-22 | 2005-01-06 | Nikolay Korokhov | Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof |
| US7045348B2 (en) * | 2002-07-22 | 2006-05-16 | Vectorlogics, Inc. | Adenoviral vector incorporating zipper peptide-modified fiber protein and uses thereof |
| AU2003252118A1 (en) * | 2002-07-22 | 2004-02-09 | Emd Lexigen Research Center | Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof |
| JP2007503843A (ja) | 2003-05-14 | 2007-03-01 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | アデノウイルス親和性の拡大 |
| WO2004111251A2 (en) * | 2003-06-11 | 2004-12-23 | The Scripps Research Institute | Modified fiber proteins for efficient receptor binding |
| US7291498B2 (en) | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| KR101915699B1 (ko) | 2010-06-10 | 2018-11-06 | 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 | 데스모글레인 2(디에스쥐2)와 아데노바이러스의 상호작용을 위한 방법 및 시스템 |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| EP3132038A4 (en) | 2014-04-18 | 2017-11-29 | Washington University | Adenoviral targeting, compositions and methods therefor |
| KR102608590B1 (ko) | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| CN107683289B (zh) * | 2015-01-26 | 2021-08-06 | 芝加哥大学 | IL13Rα2结合剂和其在癌症治疗中的用途 |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| KR20190098215A (ko) | 2016-12-21 | 2019-08-21 | 멤젠 엘엘씨 | 무장된 복제-가능 종양 분해 아데노바이러스 |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
| US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| JP2001520511A (ja) * | 1995-12-08 | 2001-10-30 | ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション | 向標的性アデノウイルス・ベクター |
| US5877011A (en) * | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
-
1999
- 1999-02-16 AU AU32940/99A patent/AU751542B2/en not_active Ceased
- 1999-02-16 KR KR1020007008959A patent/KR20010074429A/ko not_active Withdrawn
- 1999-02-16 CN CN99805041A patent/CN1297479A/zh active Pending
- 1999-02-16 NZ NZ506451A patent/NZ506451A/xx unknown
- 1999-02-16 JP JP2000531540A patent/JP2002503459A/ja active Pending
- 1999-02-16 DE DE69933550T patent/DE69933550T2/de not_active Expired - Lifetime
- 1999-02-16 CA CA002321135A patent/CA2321135A1/en not_active Abandoned
- 1999-02-16 EP EP99932506A patent/EP1070118B1/en not_active Expired - Lifetime
- 1999-02-16 BR BR9908018-4A patent/BR9908018A/pt not_active IP Right Cessation
- 1999-02-16 AT AT99932506T patent/ATE342350T1/de not_active IP Right Cessation
- 1999-02-16 US US09/250,580 patent/US6210946B1/en not_active Expired - Lifetime
- 1999-02-16 WO PCT/US1999/003233 patent/WO1999041359A1/en not_active Ceased
- 1999-02-16 IL IL13773098A patent/IL137730A0/xx unknown
-
2000
- 2000-08-17 ZA ZA200004208A patent/ZA200004208B/en unknown
- 2000-09-13 NO NO20004563A patent/NO20004563L/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002503459A5 (https=) | ||
| US6210946B1 (en) | Modified adenovirus containing a fiber replacement protein | |
| AU773202B2 (en) | Targeted adenovirus vectors for delivery of heterologous genes | |
| EP0851769B1 (en) | Gene therapy using ovine adenoviral vectors | |
| KR100796060B1 (ko) | 아데노바이러스 벡터 및 상동 재조합 현상을 줄이는 방법 | |
| US6555368B1 (en) | Capsid-modified recombinant adenovirus and methods of use | |
| EP1019499A2 (en) | Methods and compositions for inducing tumor-specific cytotoxicity | |
| JP2001505047A (ja) | 高キャパシティーアデノウイルスベクターの開発の促進に使用するためのパッケージング細胞系 | |
| KR19980702139A (ko) | 재조합 아데노바이러스 게놈의 제조방법 | |
| JP2004501646A5 (https=) | ||
| US20040038403A1 (en) | Use of spliceosome mediated RNA trans-splicing to confer cell selective replication to adenoviruses | |
| JP2970811B2 (ja) | 原核生物細胞中にポリペプチドを調製するための発現システム | |
| WO2022045366A1 (en) | Method for treating facioscapulohumeral muscular dystrophy (fshd) by targeting dux4 gene | |
| JP2003534805A (ja) | 変化した親和性を有する改変ウシアデノウイルス | |
| WO2003035883A2 (en) | Methods and compositions for inducing tumor-specific cytotoxicity | |
| US6815200B1 (en) | Modified adenovirus containing a fiber replacement protein | |
| WO2022145495A1 (en) | Method for treating spinocerebellar ataxias (sca) by targeting atxn7 gene | |
| JP2024501841A (ja) | アデノウイルス血清型３５ヘルパーベクター | |
| JPS6091984A (ja) | 新規プラスミドベクタ− | |
| JP2525413B2 (ja) | Ｌ−フェニルアラニン・アンモニアリア−ゼ発現用組換え体プラスミド及び該プラスミドを有する形質転換株 | |
| JP2002541815A (ja) | ウシアデノウイルス１型から誘導された組換えアデノウイルスおよび変異アデノウイルス | |
| JP2004290018A (ja) | 変異型アデノウイルスベクター | |
| Thompson | 8 Plasmid Cloning Vectors | |
| WO2002081716A1 (en) | Improved ovine adenovirus vector | |
| AU2002343189A1 (en) | Methods and compositions for inducing tumor-specific cytotoxicity |